Tommi P. Kilpelainen

Helsinki, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Novel PREP ligand, HUP-46, ameliorates behavioral deficits in an alpha-synuclein based Parkinson's disease model.

Novel PREP ligand, HUP-46, ameliorates behavioral deficits in an alpha-synuclein based Parkinson's disease model.

Journal: Experimental neurology

Published: September 12, 2025

Differential Effects of Pregabalin and Morphine on the Sleep-Wake Cycle and Circadian Rhythms in Mice with Neuropathic Pain.

Differential Effects of Pregabalin and Morphine on the Sleep-Wake Cycle and Circadian Rhythms in Mice with Neuropathic Pain.

Journal: Anesthesiology

Published: August 13, 2025

A prolyl oligopeptidase ligand blocks memory deficit in a repeated mild traumatic brain injury model.

A prolyl oligopeptidase ligand blocks memory deficit in a repeated mild traumatic brain injury model.

Journal: Experimental neurology

Published: May 30, 2025

5-Aminothiazoles Reveal a New Ligand-Binding Site on Prolyl Oligopeptidase Which is Important for Modulation of Its Protein-Protein Interaction-Derived Functions.

5-Aminothiazoles Reveal a New Ligand-Binding Site on Prolyl Oligopeptidase Which is Important for Modulation of Its Protein-Protein Interaction-Derived Functions.

Journal: Journal of medicinal chemistry

Published: March 28, 2024

Nonpeptidic Oxazole-Based Prolyl Oligopeptidase Ligands with Disease-Modifying Effects on α-Synuclein Mouse Models of Parkinson's Disease.

Nonpeptidic Oxazole-Based Prolyl Oligopeptidase Ligands with Disease-Modifying Effects on α-Synuclein Mouse Models of Parkinson's Disease.

Journal: Journal of medicinal chemistry

Published: May 29, 2023

A prolyl oligopeptidase inhibitor reduces tau pathology in cellular models and in mice with tauopathy.

A prolyl oligopeptidase inhibitor reduces tau pathology in cellular models and in mice with tauopathy.

Journal: Science translational medicine

Published: April 12, 2023

Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model.

Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model.

Journal: Neuropharmacology

Published: June 28, 2022

2-Imidazole as a Substitute for the Electrophilic Group Gives Highly Potent Prolyl Oligopeptidase Inhibitors.

2-Imidazole as a Substitute for the Electrophilic Group Gives Highly Potent Prolyl Oligopeptidase Inhibitors.

Journal: ACS medicinal chemistry letters

Published: July 21, 2021

Prolyl oligopeptidase inhibition reduces alpha-synuclein aggregation in a cellular model of multiple system atrophy.

Prolyl oligopeptidase inhibition reduces alpha-synuclein aggregation in a cellular model of multiple system atrophy.

Journal: Journal of cellular and molecular medicine

Published: January 15, 2021

The effect of prolyl oligopeptidase inhibitors on alpha-synuclein aggregation and autophagy cannot be predicted by their inhibitory efficacy.

The effect of prolyl oligopeptidase inhibitors on alpha-synuclein aggregation and autophagy cannot be predicted by their inhibitory efficacy.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: February 25, 2020

Prolyl oligopeptidase inhibition activates autophagy via protein phosphatase 2A.

Prolyl oligopeptidase inhibition activates autophagy via protein phosphatase 2A.

Journal: Pharmacological research

Published: October 07, 2019

Tetrazole as a Replacement of the Electrophilic Group in Characteristic Prolyl Oligopeptidase Inhibitors.

Tetrazole as a Replacement of the Electrophilic Group in Characteristic Prolyl Oligopeptidase Inhibitors.

Journal: ACS medicinal chemistry letters

Published: August 22, 2019

Showing 1-12 of 14

Last Updated: 09/26/2026